Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes

v3.25.1
Income Taxes
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes

Note 11. Income Taxes

The Company had no provision for income taxes for the years ended December 31, 2024 and 2023.

A reconciliation of the statutory U.S. federal income tax rate to the Company’s effective tax rate is as follows:

 

 

 

December 31,

 

 

 

2024

 

 

2023

 

U.S. federal statutory rate

 

 

21.0

%

 

 

21.0

%

State and local taxes

 

 

4.2

 

 

 

4.0

 

Permanent items

 

 

1.3

 

 

 

0.3

 

Change in valuation allowance

 

 

(26.5

)

 

 

(25.4

)

Other

 

 

 

 

 

0.1

 

Effective income tax rate

 

 

0.0

%

 

 

0.0

%

 

The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows (in thousands):

 

 

 

December 31,

 

 

 

2024

 

 

2023

 

Deferred tax assets:

 

 

 

 

 

 

Royalty agreement liabilities

 

$

3,913

 

 

$

1,587

 

Net operating loss

 

 

81,971

 

 

 

9,179

 

Section 174 R&D capitalization

 

 

6,288

 

 

 

4,548

 

Stock-based compensation

 

 

419

 

 

 

274

 

Accrued expenses and other

 

 

354

 

 

 

132

 

Orphan drug credit

 

 

199

 

 

 

199

 

Other tax credits

 

 

24

 

 

 

 

Startup costs

 

 

86

 

 

 

95

 

Net deferred tax assets

 

 

93,254

 

 

 

16,014

 

Valuation allowance

 

 

(93,254

)

 

 

(16,014

)

Net deferred tax assets

 

$

 

 

$

 

 

 

 

 

 

 

 

(Increase) decrease in valuation allowance

 

$

(77,240

)

 

$

4,735

 

In assessing the realizability of the net deferred tax asset, the Company considers all relevant positive and negative evidence in determining whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the NOLs. Management believes that it is more likely than not that the Company’s deferred income tax assets will not be realized. As such, there is a full valuation allowance in the amount of $93.3 million and $16.0 million against the net deferred tax assets as of December 31, 2024 and 2023, respectively. The increase in the valuation allowance of deferred tax assets as of December 31, 2024 was primarily a result of the operating losses entering into the group in the current tax year.

The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2024, the company reported no liabilities for unrecognized tax benefits along with no related interest and penalty exposure as accrued income tax on the accompanying consolidated balance sheets. Income tax returns for the tax years 2019 through 2024 remain subject to examination by the taxing authority jurisdictions.

As of December 31, 2024, the Company had net operating loss carryforwards for U.S. federal income tax purposes of $97.5 million and net operating loss carryforwards for state income tax purposes of $97.8 million. Federal tax loss carryforwards that were created prior to December 31, 2017 expire through 2037 and federal losses created after that date do not expire. State loss carryforwards expire starting in 2035. In addition, the Company has orphan drug credits of $0.2 million to reduce future federal taxes through 2039. Pursuant to Section 382 of the Internal Revenue Code of 1986, or the Code, and similar state tax law, certain substantial changes in the Company’s ownership may result in a limitation on the amount of net operating loss and tax credit carryforwards that may be used in future years. Utilization of the net operating loss and tax credit carryforwards may be subject to an annual limitation under Section 382 of the Code due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a Section 382 study through December 31, 2020. Based on the study, the Company underwent an ownership change for Section 382 purposes which occurred in February 2018. As a result of the ownership change, the Company’s net operating loss and tax credit carryforwards as of the ownership change dates are subject to limitation under Section 382; however, these limitations are not expected to result in any of the impacted net operating loss and tax credit carryforwards to expire unutilized. Any net operating losses or tax credits generated after the February 2018 change are not subject to this annual limitation. However, subsequent ownership changes, as defined by Section 382, may potentially further limit the amount of net operating loss and tax credit carryforwards that could be utilized to offset future taxable income and tax. The Company is currently open to examination under the statute of limitations by the Internal Revenue Service and state jurisdictions for the tax years ended 2019 through the current year. Carryforward tax attributes generated in years past may still be adjusted upon future examination if they have or will be used in a future period. The Company is not under examination by the Internal Revenue Service or any other jurisdictions for any tax years.

As of December 31, 2024, the Company had German corporate income tax and trade tax net operating loss carryforwards of approximately $210.3 million and $205.9 million respectively. Under current German laws, tax loss carryforwards may only be used to offset any relevant later assessment period (calendar year) of $1.2 million plus 60% of the exceeding taxable income and trade profit of such period and do not expire. In addition, certain transactions, including transfers of shares or interest in the loss holding entity, may result in the partial or total forfeiture of tax losses existing at that date. Partial or total forfeiture of tax losses may further occur in corporate reorganizations of the loss holding entity